GLG News in Healthcare
July 3, 2008
Yes - please stop the cycle of 70 deaths then pull the drug!
Analysis of: Drug Makers Say FDA Safety Focus Is Slowing New-Medicine Pipeline | online.wsj.com
Author: GLG Expert Contributor
Analysis of: Drug Makers Say FDA Safety Focus Is Slowing New-Medicine Pipeline | online.wsj.com
Author: GLG Expert Contributor
Drugs are released to the market without adequate study, then, after around 70 to 100 patient deaths due to the drug are reported, the drug is pulled from the market. Getting in front of this "problem" would improve the safety of our drug supply.
July 3, 2008An illegal use of Lumigan, now legal?
Analysis of: Longer Lashes in a Tube? Maybe Not | www.nytimes.com
Author: Steve Rubinstein, Optometrist, Sound Shore Vision Care
A few months ago, a small company tried to import Lumigan (bimatoprost), licensed by Allergan, in an eyelash applicator. It was held by the FDA as an unapproved use of a prescription medication. Now the owner of the patent is trying to import the same drug legally.
July 3, 2008
why are we going backwards
Analysis of: FDA Approves EVOLENCE®, a New Generation Collagen-Based Facial Filler | www.investor.jnj.com
Author: GLG Expert Contributor
Analysis of: FDA Approves EVOLENCE®, a New Generation Collagen-Based Facial Filler | www.investor.jnj.com
Author: GLG Expert Contributor
makes no sense to introduce a product that does not last as long as others on the market unless you are going t sell it to the patient at a substantial prce savings. Even in that scenario, needle fatigue wil eventually make the patient seek a different filler.
July 3, 2008Lung cancer profiling- May lead to improvements in care! Implications for Genentech & others.
Analysis of: Detection of Mutations in EGFR in Circulating Lung-Cancer Cells | content.nejm.org
Author: Kenneth Algazy, Clinical Professor of Medicine , University of Pennsylvania School of Medicine - CC
We may be able to analyze EGFR mutations from periperal blood of lung cancer patients. Very frequently enough tissue fromm needle biopsies are not available for analysis. This may replace the need for new biopsies.
July 3, 2008
One Drug, Many Uses -- Mostly a Very Good Idea
Analysis of: One drug, many uses. Good idea? | www.indystar.com
Author: Louis Sanfilippo, Psychiatrist, Louis Sanfilippo, MD
One Drug, Many Uses -- Mostly a Very Good Idea
Analysis of: One drug, many uses. Good idea? | www.indystar.com
Author: Louis Sanfilippo, Psychiatrist, Louis Sanfilippo, MD
‘One drug, many uses’ can make lots of sense clinically and commercially. Seeking additional FDA indications for a specific drug has obvious business benefits: greater revenue stream, improved branding, potentially longer market exclusivity, greater franchising potential of the drug into ‘improved’ formulations/uses (ie, Astra Zeneca’s Seroquel and then Seroquel XR; or GSK’s Wellbutrin...
July 3, 2008Amgen/Oral VEGF Inhibitor/Implications??? Interesting future!
Analysis of: Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer | content.nejm.org
Author: Kenneth Algazy, Clinical Professor of Medicine , University of Pennsylvania School of Medicine - CC
This oral Vascular Endothelial Growth Factor (VEGF) inhibitor appears to have activity in radioresistant differentiated thyroid carcinoma.
July 3, 2008
yes!
Analysis of: One drug, many uses. Good idea? | www.indystar.com
Author: GLG Expert Contributor
Analysis of: One drug, many uses. Good idea? | www.indystar.com
Author: GLG Expert Contributor
When drug studies are done some unexpected findings emerge. If these results can show promise and expand drug use they should be persued as the cost will likely be less than developing a whole new drug.
July 3, 2008
Safety first?
Analysis of: Drug Makers Say FDA Safety Focus Is Slowing New-Medicine Pipeline | online.wsj.com
Author: GLG Expert Contributor
Analysis of: Drug Makers Say FDA Safety Focus Is Slowing New-Medicine Pipeline | online.wsj.com
Author: GLG Expert Contributor
It is likely that with all the bad press the FDA will require many more safety studies prior to allowing a drug on the market. Many nmay not make it because it will be too prohibitive to do. There is NO magic safe pill however.
July 2, 2008
UNITED THERAPEUTICS (UTHR) SET TO ACCELERATE REVENUE GROWTH WITH FILING OF INHALED TREPROSTINIL NDA
Analysis of: New Drug Application for Inhaled Treprostinil Submitted to the U.S. Food and Drug Administration | ir.unither.com
Author: GLG Expert Contributor
Analysis of: New Drug Application for Inhaled Treprostinil Submitted to the U.S. Food and Drug Administration | ir.unither.com
Author: GLG Expert Contributor
United Therapeutics, a profitable US biotech company is about 12 months away from FDA approval of Inhaled Treprostinil for Pulmonary Arterial Hypertension. This drug will significantly add to the Company’s current 60% prostacyclin market share and help ensure the continued 30% revenue growth rate for the next 3-5 years.
July 2, 2008They'll fix this before the end of the month
Analysis of: Medicare fees to doctors fall Tuesday | news.yahoo.com
Author: David Engler, Physician, The Allergy Clinic
If this isn't fixed, it won't be long before cognitive specialties, like internal medicine and neurology, start capping their practices and not allowing new Medicare patients.
More GLG News in
Healthcare
Most Popular:
Source Article | Expert Analyses
Doctors Say Medication Is Overused in Dementia
www.nytimes.com
Medicare fees to doctors fall Tuesday
news.yahoo.com
FDA Approves EVOLENCE®, a New Generation Collagen-Based Facial Filler
www.investor.jnj.com
Why anaesthetics can make the pain worse
www.newscientist.com
FDA Panel To Weigh Heart Trials For Diabetes Meds
www.pharmalot.com
An illegal use of Lumigan, now legal?
July 3, 2008
How are we to pay for computers with a 10% drop in Medicare fees?
June 30, 2008
Obesity: Higher Healthcare Costs, Lower Productivity
June 26, 2008
Best acne care product I've seen.
June 25, 2008
Jeff is in accounting not a healthcare provider.
June 23, 2008

